A preliminary study suggests that a cocktail of three drugs could provide a quicker and better tolerated treatment for people infected with tuberculosis (TB) and could potentially work on difficult-to-treat forms of the disease that are resistant to other drugs. Unlike some existing TB treatments, the cocktail is thought to be compatible with HIV therapies, which would be an important improvement given that TB is the leading cause of death among people infected with HIV.
Researchers tested the ability of different compounds to treat tuberculosis patients recruited from clinics in Cape Town, South Africa. A combination of two existing TB drugs and one experimental compound seemed to work the best, reducing the amount of TB bacteria in patients by 99 percent in just two weeks, reports Nature News.
According to the World Health Organization, tuberculosis killed around 1.4 million people in 2010, and the vast majority of these deaths occurred in developing countries.
The triple combo was only tested in 13 patients over 14 days; longer and larger trials will be needed to confirm the results.
Meta has built a massive new language AI—and it’s giving it away for free
Facebook’s parent company is inviting researchers to pore over and pick apart the flaws in its version of GPT-3
The gene-edited pig heart given to a dying patient was infected with a pig virus
The first transplant of a genetically-modified pig heart into a human may have ended prematurely because of a well-known—and avoidable—risk.
Saudi Arabia plans to spend $1 billion a year discovering treatments to slow aging
The oil kingdom fears that its population is aging at an accelerated rate and hopes to test drugs to reverse the problem. First up might be the diabetes drug metformin.
Yann LeCun has a bold new vision for the future of AI
One of the godfathers of deep learning pulls together old ideas to sketch out a fresh path for AI, but raises as many questions as he answers.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.